Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Clinical Therapeutics

• Publication date

  2012-08-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1016/j.clinthera.2012.07.002PMID 22818870
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Varenicline

  2012cited by this paper
• Quality of Life and Utility in Patients with Non-Small Cell Lung Cancer

  2012cited by this paper
• A Meta-Analysis of Quality-of-Life Estimates for Stroke

  2012cited by this paper
• Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease

  2012cited by this paper
• Cost-Utility Analysis of Varenicline versus Existing Smoking Cessation Strategies using the BENESCO Simulation Model

  2012cited by this paper
• Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease

  2012cited by this paper
• Nicotine replacement therapy for smoking cessation.

  2012cited by this paper
• Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece

  2011cited by this paper
• Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries.

  2010cited by this paper
• Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

  2010cited by this paper
• Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis.

  2010cited by this paper
• Prevalence of chronic diseases and morbidity in primary health care in central Greece: An epidemiological study

  2010cited by this paper
• Smoking Behaviour, Involuntary Smoking, Attitudes towards Smoke-Free Legislations, and Tobacco Control Activities in the European Union

  2010cited by this paper
• A survey of tobacco dependence treatment guidelines in 121 countries

  2009cited by this paper
• Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries.

  2009cited by this paper
• A survey of tobacco dependence treatment guidelines in 31 countries.

  2009cited by this paper
• Nicotine replacement therapy for smoking cessation.

  2008cited by this paper
• Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis.

  2008cited by this paper
• Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands

  2008cited by this paper
• Análisis coste-efectividad de vareniclina (Champix) en el tratamiento del tabaquismo en España

  2008cited by this paper
• A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report.

  2008cited by this paper
• Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers.

  2008cited by this paper
• [Cost effectiveness analysis of varenicline (Champix) for the treatment of smoking in Spain].

  2008cited by this paper
• Smoking, healthcare cost, and loss of productivity in Sweden 2001

  2007cited by this paper
• Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm.

  2007cited by this paper
• PSM4 HEALTH ECONOMIC MODEL OF SMOKING CESSATION TREATMENT WITH VARENICLINE IN GERMANY

  2007cited by this paper
• Does smoking increase sick leave? Evidence using register data on Swedish workers

  2007cited by this paper
• Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

  2006cited by this paper
• Stroke incidence and prevalence in Europe: a review of available data

  2006cited by this paper
• Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

  2006cited by this paper
• Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial

  2006cited by this paper
• Efficacy of Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial

  2006cited by this paper
• Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece*

  2006cited by this paper
• Prevalence of Chronic Obstructive Pulmonary Disease and Rhinitis in Northern Greece

  2005cited by this paper
• Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study.

  2005cited by this paper
• Nicotine replacement therapy for smoking cessation.

  2004cited by this paper
• Advances in pharmacotherapy for tobacco dependence.

  2004cited by this paper
• Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study

  2003cited by this paper
• Development of the health and economic consequences of smoking interactive model

  2001cited by this paper
• Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics.

  2001cited by this paper
• Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom.

  2000cited by this paper
• Defining post-stroke recovery: implications for design and interpretation of drug trials.

  2000cited by this paper
• Stroke incidence and case fatality in southern Greece: the Arcadia stroke registry.

  1999cited by this paper
• Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation.

  1998cited by this paper
• Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling.

  1996cited by this paper
• Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes

  1988cited by this paper

• A gender perspective of smoking cessation’s health and economic value in Jordanian women: using cost effectiveness model

  2025cites this paper
• Incremental net monetary benefit of using varenicline for smoking cessation: A systematic review and meta-analysis of economic evaluation studies.

  2024cites this paper
• Motivational support intervention to reduce smoking and increase physical activity in smokers not ready to quit: the TARS RCT.

  2023cites this paper
• Does a Standard Cost-Effectiveness Threshold Exist? The Case of Greece.

  2023cites this paper
• Cost-effectiveness analysis of smoking cessation interventions with behavioral support: a study based on the Benefits of Smoking Cessation on Outcomes (BENESCO) model.

  2022cites this paper
• The Cost-Effectiveness of Nicotine Replacement Therapy Sampling in Primary Care: a Markov Cohort Simulation Model

  2022cites this paper
• Cost-Effectiveness Analysis of Smoking Cessation Interventions in the United Kingdom Accounting for Major Neuropsychiatric Adverse Events

  2021cites this paper
• Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis.

  2021cites this paper
• Cost‐effectiveness of e‐cigarettes compared with nicotine replacement therapy in stop smoking services in England (TEC study): a randomized controlled trial

  2019cites this paper
• An examination of user costs in relation to smokers using a cessation service based in the UK

  2018cites this paper
• Model‐based economic evaluations in smoking cessation and their transferability to new contexts: a systematic review

  2017cites this paper
• Mathematical Modeling in Tobacco Control Research: Initial Results From a Systematic Review.

  2016cites this paper
• Cost-effectiveness analysis of smoking-cessation treatment using electronic medical records in a cardiovascular hospital

  2016cites this paper
• Gender difference and effect of pharmacotherapy: findings from a smoking cessation service

  2016cites this paper
• [Cost-Effectiveness of Pharmacological Smoking Cessation Therapies - A Systematic Literature Review].

  2016cites this paper
• Costo-efectividad de las estatinas para el tratamiento de dislipidemia en Colombia

  2015cites this paper
• Cost-effectiveness of statins for the treatment of dyslipidemia in Colombia

  2015cites this paper
• Cost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessation

  2015cites this paper
• Comparative efficiency of health systems, corrected for selected lifestyle factors : Final report

  2015cites this paper
• 금연 치료의 재정영향 분석

  2014cites this paper
• Does varenicline increase risk of cardiovascular events ?

  2013cites this paper